Literature DB >> 16945694

Multihospital surveillance of nosocomial methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococcus, and Clostridium difficile: analysis of a 4-year data-sharing project, 1999-2002.

Terry Burger1, Deborah Fry, Renee Fusco, Maureen Luschini, Joan Bradley Mayo, Vivien Ng, Kathleen Roye-Horn, Nancy Wagner.   

Abstract

BACKGROUND: This study sought to establish a benchmark of resistant organism rates among a cohort of regional hospitals.
METHODS: The Centers for Disease Control and Prevention (CDC) definitions were used to standardize the methodology for obtaining rates per 1000 patient days of nosocomial infection and colonization with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE), and nosocomial infection with Clostridium difficile (CDIF). Only newly acquired nosocomial cases were counted. Data were reported as individual hospital control charts and as cohorted aggregate data. VHA East Coast Infection Control Professionals from 32 hospitals in New Jersey and Pennsylvania were involved.
RESULTS: Benchmarks were established with pooled mean rates for each cohort. During the observational period, a statistically significant downward trend was observed for VRE and MRSA (P = .02 and .0007, respectively), and an upward trend was observed for CDIF (P = .0256).
CONCLUSION: Benchmarks were established to compare nosocomial MRSA, VRE, and CDIF rates. Although significant changes in rates were observed, no attempt was made to establish a causal relationship between infection control practices and observed rates. However, a secondary gain was achieved through sharing best practices.

Entities:  

Mesh:

Year:  2006        PMID: 16945694     DOI: 10.1016/j.ajic.2005.08.010

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  4 in total

1.  Discontinuation of reflex testing of stool samples for vancomycin-resistant enterococci resulted in increased prevalence.

Authors:  Mandy Bodily; Kathleen M McMullen; Anthony J Russo; Nupur D Kittur; Joan Hoppe-Bauer; David K Warren
Journal:  Infect Control Hosp Epidemiol       Date:  2013-06-27       Impact factor: 3.254

2.  Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy.

Authors:  Armin Rashidi; Zhigang Zhu; Thomas Kaiser; Dawn A Manias; Shernan G Holtan; Tauseef Ur Rehman; Daniel J Weisdorf; Alexander Khoruts; Gary M Dunny; Christopher Staley
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

3.  Incidence and Outcomes Associated With Clostridium difficile Infections: A Systematic Review and Meta-analysis.

Authors:  Alexandre R Marra; Eli N Perencevich; Richard E Nelson; Matthew Samore; Karim Khader; Hsiu-Yin Chiang; Margaret L Chorazy; Loreen A Herwaldt; Daniel J Diekema; Michelle F Kuxhausen; Amy Blevins; Melissa A Ward; Jennifer S McDanel; Rajeshwari Nair; Erin Balkenende; Marin L Schweizer
Journal:  JAMA Netw Open       Date:  2020-01-03

4.  An Economic Analysis of Strategies to Control Clostridium Difficile Transmission and Infection Using an Agent-Based Simulation Model.

Authors:  Richard E Nelson; Makoto Jones; Molly Leecaster; Matthew H Samore; William Ray; Angela Huttner; Benedikt Huttner; Karim Khader; Vanessa W Stevens; Dale Gerding; Marin L Schweizer; Michael A Rubin
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.